New pill could tame overactive thyroid in Graves' disease
NCT ID NCT06984627
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This phase 2 trial tests two doses of rilzabrutinib, an oral drug, in 30 adults with Graves' disease (with or without eye problems). The main goal is to see if the drug lowers high thyroid hormone levels over 16 weeks. Researchers will also monitor safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rilzabrutinib
- What this could lead to
- If successful, this could point toward a new oral treatment option for Graves' disease that helps control thyroid hormone levels without lifelong medication.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug may not effectively lower thyroid hormones or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Investigational Site Number : 1240001
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada
-
Investigational Site Number : 1240002
RECRUITINGSurrey, British Columbia, V3T 4G8, Canada
-
Investigational Site Number : 1240003
RECRUITINGCalgary, Alberta, T2N 4L7, Canada
-
Investigational Site Number : 2760001
RECRUITINGFrankfurt, 60590, Germany
-
Investigational Site Number : 2760002
RECRUITINGEssen, 45147, Germany
-
Investigational Site Number : 3800001
RECRUITINGMilan, Milano, 20122, Italy
-
Investigational Site Number : 3800002
RECRUITINGPisa, 56126, Italy
-
Investigational Site Number : 3800003
RECRUITINGPalermo, 90127, Italy
-
Investigational Site Number : 3800004
RECRUITINGMilan, Milano, 20132, Italy
-
Investigational Site Number : 3800005
RECRUITINGMerano, Bolzano / Bozen, 39100, Italy
-
Investigational Site Number : 7240001
RECRUITINGPamplona, Navarre, 31008, Spain
-
Investigational Site Number : 7240002
RECRUITINGBarcelona, Catalunya [Cataluña], 08036, Spain
-
Investigational Site Number : 7240004
RECRUITINGSeville, Sevilla, 41009, Spain
-
Investigational Site Number : 8260001
RECRUITINGNewcastle upon Tyne, England, NE2 4HH, United Kingdom
-
Investigational Site Number : 8260003
RECRUITINGMilton Keynes, Buckinghamshire, MK6 5LD, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can a steroid shot make thyroid surgery safer?
- Targeting the immune system: a new antibody may free Graves' patients from daily drugs
- AI reads eye scans to spot thyroid disease activity and severity
- New drug aims to tame overactive thyroid in Graves' disease
- New drug aims to tame overactive thyroid in Graves' disease